Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 51 to 75 of 2384

Published guidance, NICE advice and quality standards
TitleReference numberPublishedLast updated
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancerTA310
Aflibercept for treating choroidal neovascularisationTA486
Aflibercept for treating diabetic macular oedemaTA346
Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusionTA409
Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusionTA305
Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapyTA307
Aflibercept solution for injection for treating wet age‑related macular degenerationTA294
Age-related macular degenerationNG82
Agomelatine for the treatment of major depressive episodes (terminated appraisal)TA231
AI technologies for detecting diabetic retinopathyMIB265
AI-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan imagesDG55
Air pollution: outdoor air quality and healthNG70
Air pollution: outdoor air quality and healthQS181
Airglove air warming system for venous accessMIB151
Aixplorer ShearWave Elastography for ultrasound imaging and assessing suspicious breast lesionsMIB15
Alair bronchial thermoplasty system for adults with severe difficult to control asthmaMIB71
Alcohol interventions in secondary and further educationNG135
Alcohol-use disorders: diagnosis and managementQS11
Alcohol-use disorders: diagnosis and management of physical complicationsCG100
Alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependenceCG115
Alcohol-use disorders: preventionPH24
Alcohol: preventing harmful use in the communityQS83
Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal)TA438
Alectinib for untreated ALK-positive advanced non-small-cell lung cancerTA536
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosisTA312

Results per page

  1. 10
  2. 25
  3. 50
  4. All